{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:19:23Z","timestamp":1792210763881,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":879,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.5604\/16652681.1226822","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T05:23:47Z","timestamp":1482470627000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Minimal Hepatic Encephalopathy in Cirrhosis- How Long to Treat?"],"prefix":"10.1016","volume":"16","author":[{"given":"Omesh","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/16652681.1226822_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0015","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jceh.2014.11.006","article-title":"Minimal hepatic en-cephalopathy impairs quality of life","volume":"5","author":"Agrawal","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"10.5604\/16652681.1226822_bib0020","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2001.04130.x","article-title":"Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy","volume":"96","author":"Romero-Gomez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/16652681.1226822_bib0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1440-1746.2001.02487.x","article-title":"Prevalence and natural history of subclinical hepatic encephalopa-thy in cirrhosis","volume":"16","author":"Das","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encepha-lopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.5604\/16652681.1226822_bib0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of ri-faximin versus lactulose for the treatment of hepatic en-cephalopathy","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226822_bib0040","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.510290619","article-title":"Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests","volume":"29","author":"Amodio","year":"1999","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0045","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1572-0241.2000.02265.x","article-title":"The prognostic significance of subclinical hepatic encephalopathy","volume":"95","author":"Hartmann","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/16652681.1226822_bib0050","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2004.11.028","article-title":"Minimal hepatic encephalopa-thy: diagnosis, clinical significance and recommendations","volume":"42","author":"Ortiz","year":"2005","journal-title":". J Hepatol"},{"key":"10.5604\/16652681.1226822_bib0055","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/jgh.12160","article-title":"Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy","volume":"28","author":"Jain","year":"2013","journal-title":"J Gastroenterol Hepa-tol"},{"key":"10.5604\/16652681.1226822_bib0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MEG.0b013e3282f3e6f5","article-title":"An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy","volume":"20","author":"Sharma","year":"2008","journal-title":"Eur J Gastro-enterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy","volume":"45","author":"Prasad","year":"2007","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1023\/A:1005556826152","article-title":"Efficacy of lactulose in cirrhotic patients with sub-clinical hepatic encephalopathy","volume":"45","author":"Dhiman","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226822_bib0075","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/hep.510260606","article-title":"Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy","volume":"26","author":"Watanabe","year":"1997","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2036.1997.118289000.x","article-title":"Lactulose improves psychometric testing incirrhotic patients with subclinical encephalopathy","volume":"11","author":"Horsmans","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.5604\/16652681.1226822_bib0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic enceph-alopathy (the RIME Trial)","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/16652681.1226822_bib0090","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","article-title":"Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy","volume":"140","author":"Bajaj","year":"2011","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226822_bib0095","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1572-0241.2008.01861.x","article-title":"Probiotic yogurt for the treatment of minimal hepatic encephalopathy","volume":"103","author":"Bajaj","year":"2008","journal-title":"Am J Gastroenter-ol"},{"key":"10.5604\/16652681.1226822_bib0100","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.20194","article-title":"Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis","volume":"39","author":"Liu","year":"2004","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0105","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s10620-006-9687-y","article-title":"Bifidobacterium longum with fruc-to-oligosaccharide (fos) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study","volume":"52","author":"Malaguarnera","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226822_bib0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajg.2013.08.002","article-title":"Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy","volume":"14","author":"Ziada","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"10.5604\/16652681.1226822_bib0115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/hepr.12235","article-title":"Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Alvares-da-Silva","year":"2014","journal-title":"Hepatol Res"},{"key":"10.5604\/16652681.1226822_bib0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jgh.12142","article-title":"L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials","volume":"28","author":"Bai","year":"2013","journal-title":"J Gastroen-terol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0125","first-page":"18","article-title":"The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopa-thy and nutritional status in liver cirrhosis with malnutrition","volume":"43","author":"Ndraha","year":"2011","journal-title":"Acta Med Indones"},{"key":"10.5604\/16652681.1226822_bib0130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MEG.0b013e32834696f5","article-title":"A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L- aspartate in treatment of minimal hepatic encepha-lopathy","volume":"23","author":"Mittal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0135","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s10620-008-0238-6","article-title":"Acetyl-L-carnitine treatment in minimal hepatic encephalopathy","volume":"53","author":"Malaguarnera","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226822_bib0140","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0016-5085(85)80004-4","article-title":"Branched chain ami-no acids in the treatment of latent portosystemic encepha-lopathy. A double blind placebo-controlled crossover study","volume":"88","author":"Egberts","year":"1985","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226822_bib0145","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1440-1746.2010.06318.x","article-title":"MHE. Consensus statement of a working party of the Indian national association for study of the liver","volume":"25","author":"Dhiman","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0150","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jceh.2014.02.007","article-title":"Management of covert hepatic encephalopathy","volume":"5","author":"Waghray","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"10.5604\/16652681.1226822_bib0155","series-title":"Manual of Indian Adaptation of WAIS Performance Scale","first-page":"2","author":"Ramalingaswamy","year":"1974"},{"key":"10.5604\/16652681.1226822_bib0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1440-1746.1995.tb01041.x","article-title":"Figure connection test: a universal test for assessment of mental state","volume":"10","author":"Dhiman","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/liv.12921","article-title":"Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy","volume":"36","author":"Sidhu","year":"2016","journal-title":"Liver Int"},{"key":"10.5604\/16652681.1226822_bib0170","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/17474124.2.6.785","article-title":"Management options for minimal hepatic encepha-lopathy","volume":"2","author":"Bajaj","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.20344\/amp.6035","article-title":"Minimal Hepatic En-cephalopathy: The Reality Beyond Our Eyes","volume":"28","author":"Barbosa","year":"2015","journal-title":"Acta Med Port"},{"key":"10.5604\/16652681.1226822_bib0180","first-page":"1","article-title":"Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists","volume":"29","author":"Vergara Gomez","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226822_bib0185","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.21515","article-title":"Testing for minimal hepatic encephalopathy in the United States: an AASLD survey","volume":"45","author":"Bajaj","year":"2007","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226822_bib0190","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1053\/j.gastro.2015.07.067","article-title":"Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis","volume":"149","author":"Ampuero","year":"2015","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226822_bib0195","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1872-034X.2012.01092.x","article-title":"Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study","volume":"43","author":"Kato","year":"2013","journal-title":"Hepatol Res"},{"key":"10.5604\/16652681.1226822_bib0200","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10620-010-1249-7","article-title":"Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver","volume":"55","author":"Dhiman","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226822_bib0205","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/ajg.2014.264","article-title":"Covert hepatic encephalopa-thy is independently associated with poor survival and increased risk of hospitalization","volume":"109","author":"Patidar","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.5604\/16652681.1226822_bib0210","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2009.05.056","article-title":"Secondary prophylaxis of hepatic encephalopathy: an open label randomized controlled trial of lactulose versus placebo","volume":"137","author":"Sharma","year":"2009","journal-title":"Gastro-enterology"},{"key":"10.5604\/16652681.1226822_bib0215","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalop-athy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"10.5604\/16652681.1226822_bib0220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MCG.0b013e318231faae","article-title":"Durability of rifaximin response in hepatic en-cephalopathy","volume":"46","author":"Neff","year":"2012","journal-title":"J Clin Gastroenterol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/publisherspanel.com\/icid\/pdf\/1226822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:35:36Z","timestamp":1761647736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1665268119303680"],"URL":"https:\/\/doi.org\/10.5604\/16652681.1226822","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Hepatic Encephalopathy in Cirrhosis- How Long to Treat?","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/16652681.1226822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}